Investigating a potential treatment target for neurodegenerative diseases like Alzheimer's and Parkinson's.
PME-1: Pathogenetic Role and Therapeutic Opportunity in Neurodegenerative Mixed Proteinopathies
This study is looking at how certain protein clumps in diseases like Alzheimer's and Parkinson's interact with each other and how a specific enzyme called PME-1 might influence these processes, with the hope of finding new ways to help slow down or change the course of these conditions for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10595891 on NIH RePORTER |
What this research studies
This research focuses on understanding the interactions between different protein aggregates that are commonly found in neurodegenerative diseases such as Alzheimer's and Parkinson's. It aims to explore the role of a specific enzyme, PME-1, which may contribute to the progression of these diseases by affecting the phosphorylation of key proteins involved in neurodegeneration. By studying these mechanisms, the research seeks to identify new therapeutic targets that could help slow down or modify the disease process. Patients may benefit from insights that could lead to innovative treatment options in the future.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, Parkinson's disease, or related neurodegenerative disorders.
Not a fit: Patients with neurodegenerative diseases not characterized by protein aggregation or those with other unrelated conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that slow the progression of neurodegenerative diseases, improving quality of life for patients.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in neurodegenerative diseases, suggesting potential for success in this approach.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Mouradian, M. Maral — Rutgers Biomedical and Health Sciences
- Study coordinator: Mouradian, M. Maral
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.